1
|
Chen M, Jiang G, Liu Y, Li D, Li T, Peng J, Jiang Q, You H, Ba R, Pan J, Li M, Long W, Yan J, Zhu Y, Wang Y, Xi X, Mao J, Shi X. Establishment and characterization of a novel 'double-hit' follicular lymphoma cell line, FL-SJC. J Cell Mol Med 2020; 24:7928-7938. [PMID: 32459397 PMCID: PMC7348184 DOI: 10.1111/jcmm.15425] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2020] [Revised: 05/05/2020] [Accepted: 05/06/2020] [Indexed: 01/28/2023] Open
Abstract
About 5 per cent of follicular lymphoma (FL) cases are double-hit (DH) lymphomas. Double-hit follicular lymphoma (DHFL) cell lines can improve our understanding and drug development on FL. But there are only few DHFL cell lines. Here, we established a new MYC/BCL2 DHFL cell line, FL-SJC. The cells were obtained from the hydrothorax of a patient with MYC/BCL2 DHFL and cultured for 140 passages in vitro. FL-SJC cells demonstrated CD19++ , CD20+ , CD22++ , HLA-DR+ , CD10+ , CD38+ , Lambda+ CD23- , CD5- and Kappa- . The chromosome karyotypic analysis confirmed the co-existence of t(8;22)(q24;q11) and t(14;18)(q32;q21), as well as additional abnormalities involving chromosomes 2 and 3. Fluorescence in situ hybridization analysis (FISH) showed IGH/BCL2 fusion gene and the MYC rearrangement. In addition, the FL-SJC cells displayed KMT2D/MLL2 and CREBBP gene mutations. After subcutaneous inoculation of FL-SJC cells, the SCID mice developed solid tumour masses within 6-8 weeks. FL-SJC cells were proven to be free of Epstein-Barr (EB) virus infection and be multidrug-resistant. In a conclusion, the FL-SJC cell line has been identified as a novel MYC/BCL2 double-hit follicular lymphoma that can be used as a potentially available tool for the clinical and basic research, together with the drug development for MYC/BCL2 DHFL.
Collapse
Affiliation(s)
- Min Chen
- Affiliated Hospital of Jiangsu University, Zhenjiang, China
| | - Guoxiong Jiang
- Affiliated Hospital of Jiangsu University, Zhenjiang, China.,Jiangdu People's Hospital, Yangzhou, China
| | - Yichen Liu
- Affiliated Hospital of Jiangsu University, Zhenjiang, China
| | - Dongya Li
- Affiliated Hospital of Jiangsu University, Zhenjiang, China
| | - Tiantian Li
- Affiliated Hospital of Jiangsu University, Zhenjiang, China
| | - Jie Peng
- Affiliated Hospital of Jiangsu University, Zhenjiang, China
| | - Qian Jiang
- Affiliated Hospital of Jiangsu University, Zhenjiang, China
| | - Haiyan You
- Affiliated Hospital of Jiangsu University, Zhenjiang, China
| | - Rong Ba
- Affiliated Hospital of Jiangsu University, Zhenjiang, China
| | - Jinlan Pan
- Affiliated Hospital of Suzhou University, Suzhou, China
| | - Mei Li
- Affiliated Hospital of Jiangsu University, Zhenjiang, China
| | - Weiguo Long
- Affiliated Hospital of Jiangsu University, Zhenjiang, China
| | - Jinsong Yan
- The Second Hospital of Dalian Medical University, Dalian, China
| | - Yan Zhu
- Affiliated Hospital of Jiangsu University, Zhenjiang, China
| | - Yun Wang
- State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Xiaodong Xi
- State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jianhua Mao
- State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Xiaofeng Shi
- Affiliated Hospital of Jiangsu University, Zhenjiang, China.,The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China
| |
Collapse
|